Back

Discontinuation of guideline-recommended heart failure treatments after a first hospitalization for heart failure - An analysis from the SwedeHF registry

21 May 2022 (11:25 - 11:40)
Organised by:
Congress Presentation Part of: Young Investigator Award: clinical research Pharmacotherapy HFA Premium Access Heart Failure 2022

3 More presentations in this session

Presentation thumbnail
Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial
Doctor J. Butt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Distinct pathophysiological pathways in women and men with heart failure
Doctor A. Ravera (Brescia, IT)
Abstract Slides Video
Presentation thumbnail
The effect of dapagliflozin according to iron status and its effect on iron metabolism: insights from DAPA-HF
Doctor K. Docherty (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award: clinical research
Video

The Event

Event poster

Heart Failure 2022

21 May 2022 11:25 CET
You may be interested in
thumbnail
Congress Presentation
Persistence to guideline-based therapy newly prescribed after a hospitalization for heart failure. Data from two large cohorts in the US and Germany.
20 May 2023
thumbnail
Congress Presentation
Is downtitration of diuretic therapy safe in patients with heart failure?
20 May 2023
thumbnail
Congress Presentation
History of betablocker treatment breaks and risk of ventricular tachyarrhythmias among patients with heart failure and implantable cardioverter defibrillator: a nationwide cohort study
29 August 2022
thumbnail
Congress Presentation
Temporal trends in cause-specific readmissions and their risk factors in heart failure patients in Sweden
30 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources